US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Prosus NV (PK) (PROSF) 銘柄情報

Prosus NV (PK) (PROSF)

45.45

0.00

(0.00%)

終了 6月6日 5:00AM

Prosus NV (PK) (PROSF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

45.45

( - )

買値

45.44

売値

49.19

出来高

507

0.00 日の範囲 0.00

44.05 52 週間の範囲 72.77

時価総額

前日終値

45.45

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 3,523,334

発行済株式数

2,315,995,974

配当利回り

0.22

PER

5.89

1 株当たり利益 (EPS)

7.62

歳入

6.83B

純利益

13.41B

Prosus N.V. engages in the e-commerce and internet businesses in Asia, Europe, Latin America, North America, and internationally. It operates internet platforms, such as classifieds, payments and fintech, food delivery, education technology, Etail, ventures, tencent, and other platforms. It also pro... Prosus N.V. engages in the e-commerce and internet businesses in Asia, Europe, Latin America, North America, and internationally. It operates internet platforms, such as classifieds, payments and fintech, food delivery, education technology, Etail, ventures, tencent, and other platforms. It also provides online food delivery service. The company was formerly known as Myriad International Holdings N.V. and changed its name to Prosus N.V. in August 2019. Prosus N.V. was incorporated in 1994 and is headquartered in Amsterdam, the Netherlands. Prosus N.V. operates as a subsidiary of Prosus N.V. 詳細を表示

セクター

Media

業界

Interactive Multi-media

ウェブサイト

www.prosus.com

本社

Amsterdam, Netherlands

設立

1994

Prosus NV (PK) is listed in the Media sector of the その他OTC with ticker PROSF. The last closing price for Prosus NV (PK) was US$45.45. Over the last year, Prosus NV (PK) shares have traded in a share price range of US$ 44.05 to US$ 72.77.

Prosus NV (PK) currently has 2,315,995,974 shares in issue. The market capitalisation of Prosus NV (PK) is US$105.26 billion. Prosus NV (PK) has a price to earnings ratio (PE ratio) of 5.89.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0.72	1.60965794769	44.73	46.73	44.05	16603	45.39347601	CS
12	-7.7256	-14.5284679439	53.1756	53.558	44.05	9159	46.84253652	CS
26	-15.12	-24.9628528975	60.57	65.0695	44.05	8851	51.08243313	CS
52	-8.548	-15.8302159339	53.998	72.77	44.05	7429	56.60766131	CS
156	-25.944	-36.3391881671	71.394	77.615	26.75	20659	36.27584444	CS
260	-59.7505	-56.7967832853	105.2005	105.2005	26.75	14799	46.0248588	CS

PROSF - Frequently Asked Questions (FAQ)

What is the current Prosus NV (PK) share price?

The current share price of Prosus NV (PK) is US$ 45.45

How many Prosus NV (PK) shares are in issue?

Prosus NV (PK) has 2,315,995,974 shares in issue

What is the market cap of Prosus NV (PK)?

The market capitalisation of Prosus NV (PK) is USD 105.26B

What is the 1 year trading range for Prosus NV (PK) share price?

Prosus NV (PK) has traded in the range of US$ 44.05 to US$ 72.77 during the past year

What is the PE ratio of Prosus NV (PK)?

The price to earnings ratio of Prosus NV (PK) is 5.89

What is the cash to sales ratio of Prosus NV (PK)?

The cash to sales ratio of Prosus NV (PK) is 15.26

What is the registered address of Prosus NV (PK)?

The registered address for Prosus NV (PK) is Symphony Offices, Amsterdam, Noord-Holland, 1082 MS

What is the Prosus NV (PK) website address?

The website address for Prosus NV (PK) is www.prosus.com

Which industry sector does Prosus NV (PK) operate in?

Prosus NV (PK) operates in the Interactive Multi-Media sector

US Market News

US Market News 4分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 4分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 6分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 9分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 10分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 13分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 13分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 13分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 17分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 17分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 18分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 19分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 20分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 21分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 22分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 22分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 22分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 23分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 23分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 24分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 26分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 29分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

iNAV Xtrackers II US Tre...

FTAC Emerald Acquisition

New Energy Solar

Churchill Capital Corp IV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。